ISSAID/EMQN Best Practice Guidelines for the Genetic Diagnosis of Monogenic Autoinflammatory Diseases in the Next-Generation Sequencing Era.


Journal

Clinical chemistry
ISSN: 1530-8561
Titre abrégé: Clin Chem
Pays: England
ID NLM: 9421549

Informations de publication

Date de publication:
01 04 2020
Historique:
received: 26 09 2019
accepted: 08 01 2020
pubmed: 17 3 2020
medline: 3 11 2020
entrez: 17 3 2020
Statut: ppublish

Résumé

Monogenic autoinflammatory diseases are caused by pathogenic variants in genes that regulate innate immune responses, and are characterized by sterile systemic inflammatory episodes. Since symptoms can overlap within this rapidly expanding disease category, accurate genetic diagnosis is of the utmost importance to initiate early inflammation-targeted treatment and prevent clinically significant or life-threatening complications. Initial recommendations for the genetic diagnosis of autoinflammatory diseases were limited to a gene-by-gene diagnosis strategy based on the Sanger method, and restricted to the 4 prototypic recurrent fevers (MEFV, MVK, TNFRSF1A, and NLRP3 genes). The development of best practices guidelines integrating critical recent discoveries has become essential. The preparatory steps included 2 online surveys and pathogenicity annotation of newly recommended genes. The current guidelines were drafted by European Molecular Genetics Quality Network members, then discussed by a panel of experts of the International Society for Systemic Autoinflammatory Diseases during a consensus meeting. In these guidelines, we combine the diagnostic strength of next-generation sequencing and recommendations to 4 more recently identified genes (ADA2, NOD2, PSTPIP1, and TNFAIP3), nonclassical pathogenic genetic alterations, and atypical phenotypes. We present a referral-based decision tree for test scope and method (Sanger versus next-generation sequencing) and recommend on complementary explorations for mosaicism, copy-number variants, and gene dose. A genotype table based on the 5-category variant pathogenicity classification provides the clinical significance of prototypic genotypes per gene and disease. These guidelines will orient and assist geneticists and health practitioners in providing up-to-date and appropriate diagnosis to their patients.

Sections du résumé

BACKGROUND
Monogenic autoinflammatory diseases are caused by pathogenic variants in genes that regulate innate immune responses, and are characterized by sterile systemic inflammatory episodes. Since symptoms can overlap within this rapidly expanding disease category, accurate genetic diagnosis is of the utmost importance to initiate early inflammation-targeted treatment and prevent clinically significant or life-threatening complications. Initial recommendations for the genetic diagnosis of autoinflammatory diseases were limited to a gene-by-gene diagnosis strategy based on the Sanger method, and restricted to the 4 prototypic recurrent fevers (MEFV, MVK, TNFRSF1A, and NLRP3 genes). The development of best practices guidelines integrating critical recent discoveries has become essential.
METHODS
The preparatory steps included 2 online surveys and pathogenicity annotation of newly recommended genes. The current guidelines were drafted by European Molecular Genetics Quality Network members, then discussed by a panel of experts of the International Society for Systemic Autoinflammatory Diseases during a consensus meeting.
RESULTS
In these guidelines, we combine the diagnostic strength of next-generation sequencing and recommendations to 4 more recently identified genes (ADA2, NOD2, PSTPIP1, and TNFAIP3), nonclassical pathogenic genetic alterations, and atypical phenotypes. We present a referral-based decision tree for test scope and method (Sanger versus next-generation sequencing) and recommend on complementary explorations for mosaicism, copy-number variants, and gene dose. A genotype table based on the 5-category variant pathogenicity classification provides the clinical significance of prototypic genotypes per gene and disease.
CONCLUSIONS
These guidelines will orient and assist geneticists and health practitioners in providing up-to-date and appropriate diagnosis to their patients.

Identifiants

pubmed: 32176780
pii: 5807902
doi: 10.1093/clinchem/hvaa024
doi:

Substances chimiques

Adaptor Proteins, Signal Transducing 0
Cytoskeletal Proteins 0
Intercellular Signaling Peptides and Proteins 0
NOD2 protein, human 0
Nod2 Signaling Adaptor Protein 0
PSTPIP1 protein, human 0
TNFAIP3 protein, human EC 3.4.19.12
Tumor Necrosis Factor alpha-Induced Protein 3 EC 3.4.19.12
ADA2 protein, human EC 3.5.4.4
Adenosine Deaminase EC 3.5.4.4

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

525-536

Informations de copyright

© American Association for Clinical Chemistry 2020.

Auteurs

Yael Shinar (Y)

Laboratory of FMF, Amyloidosis and Rare Autoinflammatory Diseases, Heller Institute, Sheba Medical Center, Tel Hashomer, Israel.

Isabella Ceccherini (I)

UOC Medical Genetics, IRCCS Istituto Giannina Gaslini, Genova, Italy.

Dorota Rowczenio (D)

National Amyloidosis Centre, UCL Medical School, London, UK.

Ivona Aksentijevich (I)

National Human Genome Research Institute, Bethesda, MD.

Juan Arostegui (J)

Department of Immunology, Hospital Clínic, Barcelona, Spain.
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Eldad Ben-Chétrit (E)

Rheumatology Unit, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.

Guilaine Boursier (G)

Department of Medical Genetics, Rare Diseases and Personalized Medicine, Reference Center CEREMAIA, CHU Montpellier, University of Montpellier, Montpellier, France.

Marco Gattorno (M)

Center for Autoinflammatory Diseases and Immunodeficiency, IRCCS Giannina Gaslini, Genova.

Hasmik Hayrapetyan (H)

Center of Medical Genetics and Primary Health Care, Yerevan, Armenia.

Hiroaki Ida (H)

Department of Medicine, Division of Respirology, Neurology and Rheumatology, Kurume University School of Medicine, Kurume, Japan.

Nobuo Kanazawa (N)

Department of Dermatology, Wakayama Medical University, Wakayama, Japan.

Helen J Lachmann (HJ)

National Amyloidosis Centre, UCL Medical School, London, UK.

Anna Mensa-Vilaro (A)

Department of Immunology, Hospital Clínic, Barcelona, Spain.

Ryuta Nishikomori (R)

Department of Pediatrics and Child Health, Kurume University School of Medicine, Kurume, Japan.

Christian Oberkanins (C)

ViennaLab Diagnostics, Vienna, Austria.

Laura Obici (L)

Amyloidosis Research and Treatment Centre, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

Osamu Ohara (O)

Department of Applied Genomics, Kazusa DNA Research Institute, Kisarazu, Japan.

Seza Ozen (S)

Department of Pediatrics, Hacettepe University, Ankara, Turkey.

Tamara Sarkisian (T)

Center of Medical Genetics and Primary Health Care, Yerevan, Armenia.

Katie Sheils (K)

European Molecular Genetics Quality Network (EMQN), Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester, UK.

Nicola Wolstenholme (N)

European Molecular Genetics Quality Network (EMQN), Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester, UK.

Evelien Zonneveld-Huijssoon (E)

Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Marielle E van Gijn (ME)

Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Isabelle Touitou (I)

Department of Medical Genetics, Rare Diseases and Personalized Medicine, Reference Center CEREMAIA, CHU Montpellier, University of Montpellier, Montpellier, France.
Stem Cells, Cellular Plasticity, Regenerative Medicine and Immunotherapies, INSERM, Montpellier, France.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH